# Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

> **NCT06994845** · PHASE3 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 31 (estimated)

## Conditions studied

- Primary Immunoglobulin A Nephropathy (IgAN)

## Interventions

- **DRUG:** iptacopan

## Key facts

- **NCT ID:** NCT06994845
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-27
- **Primary completion:** 2030-06-28
- **Final completion:** 2030-06-30
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06994845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06994845, "Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06994845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*